Sandoz has become the first company to gain the FDA approval to produce a generic version of Atacand (candesartan cilexetil), the popular heart drug that generated an estimated 120 million in domestic sales last year.
Sandoz has become the first company to gain FDA approval to produce a generic version of Atacand (candesartan cilexetil), the popular heart drug that generated an estimated $120 million in domestic sales last year.
“Sandoz is proud to be the first generic company to market this important generic treatment option to patients in the US,” said Don DeGolyer, president of Sandoz US. “The launch of candesartan further expands our offering of high-quality, affordable cardiology medicines.”
Candesartan cilexetil tablets are used to treat heart failure in some adults and hypertension in adults and children aged 1 to 17 years.
Sandoz’s generic candesartan cilexetil tablets will be available in 4-mg, 8-mg, 16-mg, and 32-mg strength tablets.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
FDA Expands Kerendia’s Use to Treat Common Form of Heart Failure
July 14th 2025Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic kidney disease (CKD) associated with type 2 diabetes. This new approval extends its use to a broader patient population.
Read More